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Abstract
Background: Extensive prostate specific antigen screening for prostate cancer generates a high number of unnecessary
biopsies and over-treatment due to insufficient differentiation between indolent and aggressive tumours. We hypothesized
that seminal plasma is a robust source of novel prostate cancer (PCa) biomarkers with the potential to improve primary
diagnosis of and to distinguish advanced from indolent disease.
Methodology/Principal Findings: In an open-label case/control study 125 patients (70 PCa, 21 benign prostate hyperplasia,
25 chronic prostatitis, 9 healthy controls) were enrolled in 3 centres. Biomarker panels a) for PCa diagnosis (comparison of
PCa patients versus benign controls) and b) for advanced disease (comparison of patients with post surgery Gleason score
,7 versus Gleason score .7) were sought. Independent cohorts were used for proteomic biomarker discovery and testing
the performance of the identified biomarker profiles. Seminal plasma was profiled using capillary electrophoresis mass
spectrometry. Pre-analytical stability and analytical precision of the proteome analysis were determined. Support vector
machine learning was used for classification. Stepwise application of two biomarker signatures with 21 and 5 biomarkers
provided 83% sensitivity and 67% specificity for PCa detection in a test set of samples. A panel of 11 biomarkers for
advanced disease discriminated between patients with Gleason score 7 and organ-confined (,pT3a) or advanced ($pT3a)
disease with 80% sensitivity and 82% specificity in a preliminary validation setting. Seminal profiles showed excellent pre-
analytical stability. Eight biomarkers were identified as fragments of N-acetyllactosaminide beta-1,3-N-acetylglucosaminyl-
transferase, prostatic acid phosphatase, stabilin-2, GTPase IMAP family member 6, semenogelin-1 and -2. Restricted sample
size was the major limitation of the study.
Conclusions/Significance: Seminal plasma represents a robust source of potential peptide makers for primary PCa
diagnosis. Our findings warrant further prospective validation to confirm the diagnostic potential of identified seminal
biomarker candidates.
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Introduction
Prostate cancer (PCa) is the second most frequently diagnosed
cancer and the sixth leading cause of cancer death in males
worldwide [1]. The introduction of serum prostate specific antigen
(PSA) screening led to a significant increase in the number of
diagnosed cases [2] but failed to demonstrate a statistically
significant prostate cancer mortality benefit [3]. Ninety-five
percent of men with PSA-detected cancer who are followed for
12 years do not die from PCa, even in the absence of definite
treatment, such as radical prostatectomy, radiation therapy or
hormonal therapy [3].
This has significantly exaggerated our current inability to make
evidence-based recommendations on treatment choices according
to tumour behaviour, namely clinically insignificant, or indolent
disease and clinically significant, or advanced disease [4].
Therefore, new screening modalities are urgently needed to
reduce the number of men who require biopsy and to improve the
discriminatory accuracy between indolent tumour that has a
favourable clinical prognosis even without intervention, and
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disease that is likely to have already clinically advanced, in order to
reduce over-diagnosis and over-treatment.
Proteomic biomarker screening has become popular during the
past decade. Blood, urine, prostatic fluids, and prostatic tissue have
been evaluated as biomarker source. Several candidate biomarkers
found in those studies were introduced as biomarkers in an
attempt to address the clinical needs for discrimination of indolent
and advanced disease [5-7]. However, all the single biomarkers
currently available, lack diagnostic accuracy for routine clinical
application. The high biological variability of prostate cancer
suggests that a distinct clearly defined set of biomarkers, rather
than a single biomarker, may be more efficient to accurately assess
the disease. Recent technical advances, especially in mass
spectrometry and computation, allow application of proteomic
profiling for discovery of multiple protein biomarker.
Recently, we identified and validated a proteomic pattern of 12
naturally occurring, urinary peptide biomarkers by capillary
electrophoresis mass spectrometry (CE-MS), capable to detect
PCa using first stream urine with 90% sensitivity and 61%
specificity [8,9]. These experiments suggested that prostatic fluids
may serve as source of biomarkers [10]. On the basis of these
findings, we hypothesized that seminal plasma might offer a robust
source to identify novel PCa protein maker profiles. This study
aimed at a systematic assessment of pre-analytical seminal plasma
stability and of its suitability for the development of PCa
biomarker panels.
Results
Patients’ clinical outcome
In total 70 patients with PCa, 21 patients with benign prostate
hyperplasia (BPH), 25 patients with chronic prostatitis (CP) and 9
healthy control (HC) were included in the study (Table 1 and
Figure 1). CP and HC groups were significantly younger than the
patients in the PCa and the benign prostate hyperplasia (BPH)
groups (Table 1). As expected PSA levels were significantly lower
in CP and HC compared to BPH (0.98 – 6.70 ng/ml) or PCa (2.0
– 20 ng/ml) in both, training and test set (p,0.05, Mann Whitney
test, two-tailed; Table 1). The TNM classification revealed 60
organ confined (#pT2c) and 10 advanced ($pT3a) PCa. The
allocation of patients to low and high risk groups varied
considerably between classification systems (Table 1).
Proteomic profiles
CE-MS analysis yielded high resolution profiles (Figure 2, Table
S1). For preliminary profile calibration we used synthetic isotope
labelled peptides as reference. This pre-calibration allowed
definition of 287 ‘‘house-keeping peptides’’ as reference mass
and migration time data points. As ion signal intensity (amplitude)
showed significant variability, the signals of 46 highly abundant
peptides were used as internal standard peptides for signal
normalization (Table S2). These peptides were present in .97%
of analyzed samples and showed lowest signal variability. The
procedure to use ‘‘internal standard’’ for amplitude normalization,
was shown to be an easy and reliable method to address both
analytical and dilution variances in a single calibration step [11].
Tandem mass spectrometry [12-14] identified 141 native seminal
peptides representing 47 different parental proteins (Table S3).
Eighty-eight identified peptides (83/141, 59%) were fragments of
semenogelin-1 or -2, by far the most abundant peptides of the low
molecular weight seminal proteome.
Biomarker discovery
Study A: Diagnostic markers. For diagnostic biomarker
discovery we divided the available 125 samples into a discovery set
with 22 PCa, 14 CP; 9 BPH and 5 HC samples and the remaining
48 PCa, 12 BPH, 11 CP, and 4HC samples into an independent
test set (Figure 1). Multiple testing statistics resulted in 21
discriminatory polypeptides significantly altered between patients
with and without prostate cancer (Table 2 and Figure 3). Six out of
the 21 polypeptides were identified as fragments of N-acetyllacto-
saminide beta-1,3-N-acetylglucosaminyltransferase, prostatic acid
phosphatase, semenogelin-1 and -2 (Table 3). In order to define
biomarker candidates reliably differentiating PCa and BPH, we
compared BPH vs. PCA, BPH vs. CP & HC, and BPH vs. PCa &
CP & HC using appropriate multiple testing statistics. Five
polypeptides were significant in all three tests suggesting suitability
of these candidates to specifically identify BPH and therefore to
exclude presence of PCa (Table 2, Figure 3). One of them was a
fragment of GTPase IMAP family member 6 (Table 3).
We applied a two-step approach: (i) a first panel (21
polypeptides, 21PP) to discern PCa and BPH from inflammatory
and healthy prostate; (ii) a second panel (5 polypeptides, 5PP) to
differentiate PCa and BPH. Both signatures were trained in the
discovery cohort (Figure 1) using support vector machine
algorithms (SVM) and reached AUC values of 100% (95% CI
93%–100%) for 21PP and 99% (95% CI 90%–99%) for 5PP.
For confirmation of classification performance of the biomarker
signatures we applied the combination of 21PP and 5PP to an
independent test set of 48 PCa, 12 BPH, 11 CP, and 4HC (Figure
1). Samples positive for 21PP (above the classification cut off) were
re-classified using 5PP to specifically identify BPH excluding PCa.
Therefore, samples positive for 21PP and negative for 5PP were
considered as PCa, samples positive in either panels were
considered as BPH and samples negative for 21PP (below the
classification cut off) were considered as CP or HC control
samples. This approach correctly identified 40 out of 48 PCa
samples [83% sensitivity (95% CI 70%–93%)], 6 of 12 BPH and
12 of 15 controls [67% specificity (95% CI 46%–83%)]. AUC
value was 75% (95% CI 64%–83%, P=0.0001). The observed
diagnostic performance was as high as the performance of PSA as
reference, which showed 87% sensitivity (95% CI 75%–97%) and
59% specificity (95% CI 40%–80%).
Study B: Advanced disease biomarkers. For advanced
disease biomarker discovery we divided the available 70 PCa
samples into a training set with 37 PCa samples (21 post-surgery
Gleason score ,7, 16 post-surgery Gleason score .7). The
remaining 33 samples with post-surgery Gleason score 7 were used
as a test set. Comparison of the 21 GS ,7 patients (,pT3a) to 16
GS .7 patients (11 ,pT3a, 5 pT3a) using statistics corrected for
multiple testing resulted in 11 biomarker candidates with a
fragment of stabilin-2 among them (Tables 2 and 3). These as
pattern (11PP) were found to classify the cohort with an AUC of
99% (95% CI 87%–100%, Figure 1).
To test the performance of the biomarkers associated with
advanced disease, 11PP was applied to the test set of patients with
post-surgery Gleason score 7 that were not used for biomarker
discovery. Of the 33 samples, 9 scored as advanced (above the
classification cut off) and 24 as indolent tumour (below the
classification cut off).
In clinical practice various classification systems are used to
estimate risk for prostate cancer progression. Therefore, we
compared the performance of our biomarkers to five commonly
used systems (Table S4): 11PP results were significantly correlated
to TNM stages [rho 0.423 (95% CI 0.093 to 0.669), P = 0.0142],
EAU score [rho 0.408 (95% CI 0.076 to 0.659), P = 0.0183], and
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NCCN score [rho 0.365 (95% CI 0.024 to 0.629), P = 0.0370]
(Figure 4A–C), while CAPRA, RTOG and D’Amico score were
not correlated (data not shown). Using EAU classification as
reference standard, 11PP correctly identified 4/5 advanced
($pT3a) and 23/28 organ-confined (,pT3a) tumours, resulting
in an AUC of 83% (95% CI 66%–94%, P=0.0055, two sided
power b=0.84, Figure 5D). Sensitivity was 80% (95% CI 29%–
97%) and specificity was 82% (95% CI 63%–94%)].
Study C: Assessment of biomarker stability and
reproducibility. Seminal plasma demonstrated robust pre-
analytical stability at room temperature. The obtained profiles
were highly similar without massive disappearance or formation of
degraded fragments. An average of 18876202 peptides (Figure
5A) was detected in 14 replicates. Investigation of the 21PP in
these 14 replicates to quantify time dependency of stability
revealed a significant decrease of SVM scores over time with
Spearman’s rho of –0.576 (95% CI –0.854 to –0.07, P = 0.0379,
Figure 5B). Regression analysis unveiled a decrease rate of -0.05
a.u. (,2%) per hour. 5PP and 11PP displayed no significant time
dependency. Analytical precision of the established SVM classi-
fiers was assessed in 15 independent replicates. Mean classification
scores were 0.61960.07, 2.29060.81, and -1.23960.18 resulting
in coefficients of variations of 2.2%, 10.8%, and 6.1% for 21PP,
5PP, and 11PP, respectively (Figure 5C).
Discussion
We hypothesized that seminal plasma is a robust source of novel
PCa peptide maker profiles with the potential to improve primary
diagnosis of prostate cancer and to distinguish advanced from
indolent disease.
In contrast to earlier reports of proteomic profiling of seminal
plasma using tryptic digestion [15], we used native seminal plasma
for biomarker proteomic analysis. The main advantages of this
top-down approach on naturally occurring peptides include the
ability to directly detect combinations of post-translational
modifications, sequence variants, and degradation products. We
detected almost 2,000 different seminal peptides #20 kDa. Those
were fragments of larger parental proteins, which were partially
also detected earlier using tryptic digests. However, our approach
also identify yet unknown seminal constituents (Table S3).
The generation of these naturally occurring peptides depends
on the proteolytic liquefaction of the ejaculate and results in
multiple proteolytic fragments of seminal proteins. Disease
associated alterations in this proteolytic liquefaction process might
account for our observation, that some naturally occurring
fragments show significantly altered seminal levels and others of
the same parental protein do not. Therefore, pre-analytical
stability and analytical reproducibility are of utmost importance
for successful biomarker discovery and clinical validation. A first
milestone in the current study was the development of a simple
and reproducible sampling procedure consistent with a clinical
routine setting. We allowed liquefaction to reach a final steady
Figure 1. Flow chart of study design. For biomarker discovery in total 125 seminal plasma samples were used from 70 patients with PCa, 21
patients with benign prostate hyperplasia (BPH), 25 patients with chronic prostatitis (CP) and 9 healthy control (HC). This pool of available samples
was used in varying composition in three study arms. In study A ‘‘Diagnostic Markers’’ 50/125 patients with and without prostate cancer (22 PCa, 14
CP; 9 BPH and 5 HC) were used for biomarker discovery and the remaining 75/125 patients (48 PCa, 12 BPH, 11 CP, and 4HC) were used for diagnostic
performance tests. In Study B ‘‘Advanced Disease Markers’’ available PCa samples (n = 70) were stratified according to Gleason score. For biomarker
discovery patients with Gleason score ,7 (n = 21) and Gleason score .7 (n = 16) were compared. The remaining 33/70 patients with Gleason score 7
(28 indolent disease ,pT3a and 5 $pT3a advanced disease according EUA guidelines) were used for testing clinical performance. Furthermore, in
study C preliminary assessment of stability and precision of the approach was performed.
doi:10.1371/journal.pone.0067514.g001
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state, documented by a constant number of detectable polypep-
tides over time (Figure 5A), but controlled time to sample storage
at –80uC to be below 60 min to avoid interference with time-
dependent biomarker instability at room temperature (Figure 5B).
Samples of prostate tissue, blood, seminal plasma, and urine
with and without prostate massage are currently intensively
analyzed for potential PCa biomarkers [5,6]. While tissue is
expected to be proximal to the origin of the disease and to
correlate with highest biomarker concentrations, the sampling of
tissue is related to invasive intervention with all risks and
limitations. In contrast, especially seminal plasma and urine are
easily accessible. However, proteolytic processing is of increasing
importance for the exploitation of markers from bodyfluids. Our
preliminary data on seminal plasma stability (Figure 5A/B) did not
provide evidence for massive post-sampling degradation as in
contrast was observed for blood serum [16] or plasma [17].
Therefore seminal plasma might combine high proximity to the
prostate gland as site of the tumour only exceeded by direct
prostate tissue sampling with the excellent stability and accessibil-
ity of urine [18–21], making it a highly promising source for
potential PCa biomarkers.
We were able to define and validate robust biomarker signatures
for the diagnosis of PCa. The sensitivity of 83% (95% CI 70%–
93%) to diagnose PCa was highly comparable with those reported
earlier for CE-MS based urinary biomarker signatures (sensitivity
86% to 90%). The specificity of 67% (95% CI 46%–83%) was
slightly better than their urinary counterparts of 59% and 61%,
respectively [8,9].
In addition, we discovered a seminal biomarker signature,
which distinguished (P=0.0055) patients with post-surgery
Gleason score 7 with indolent (,pT3a) or advanced ($pT3a)
disease with high sensitivity and specificity of 80% and 82%,
respectively. Current clinical routine using serum PSA level and
pre-surgery Gleason sum score to identify advanced disease
remains inadequate, as the majority of screening detected PCa
have PSA levels between 4–10 ng/ml and moderate Gleason sum
scores of 6 and 7. Therefore, these biomarkers, which are based on
post-surgery outcome data as reference standard, might represent
a future possibility for a non-invasive pre-surgery differentiation of
organ confined and advanced tumour stages. In addition, tumour
evaluation by pre-surgery Gleason score grading requires invasive
procedures to obtain tissue specimens, and is hampered by
significant inter-operator variability and discrepancies between
pre- and post-surgery scores in as many as 35% of cases [22].
Furthermore, among patients with clinically localised disease
(tumour stages T1 and T2), approximately 30% are found to have
locally advanced tumours following radical surgery. Therefore,
there is a real risk of under-treatment in this group of patients, if
managed by surveillance. In future the biomarker profile might
help to avoid under-treatment in these patients with unclear
clinical presentation.
One of the differentially expressed seminal proteins was prostate
acidic phosphatase (ACPP), which is a negative regulator of cell
growth in LNCap cells [23]. Down regulation of cellular ACPP is
associated with androgen-independent tumour growth and high
tumorigenicity of advanced PCa grades [23].
We observed semenogelin-1 fragment 316–344 (ID18990) as
one of the 21 differentially regulated polypeptides (Table 2 and
Table 3). While this fragment can directly be assigned to KLK3
( = PSA) cleavage at site 315 (SSIY-SQTE), this holds not true for
the other observed semenogelin fragments. These cannot be
explained by KLK3 cleavage alone, implicating presence of a
more complex protease activity network with multiple downstream
cleavage events after initial KLK3 cleavage It is well known that
there are mutual activation and inhibition mechanisms within the
liquefaction cascade [24], which could lead to different ‘‘down-
Figure 2. Human seminal plasma polypeptide profiles. Capillary electrophoresis coupled to mass spectrometry profiling of humane seminal
plasma revealed a total of 1784 peptides. The synthetic peptides spiked to the samples for pre-calibration purposes are marked with white arrows.
Normalized molecular weight (700-25.000 Da) in logarithmic scale is plotted against normalized migration time (15-45 min). The mean signal intensity
of the polypeptide peak is given in 3D-depiction. Compiled data sets of PCa (case) combined all controls and also separately CP (control), BPH
(control) and HC (control) from training set are shown.
doi:10.1371/journal.pone.0067514.g002
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stream’’ cleavage patterns. The role of the potential peptidases
involved in the formation of the specific peptide fragments cannot
be judged at present. In further experimental studies the possible
involvement of exopeptidases should be addressed, which might
further process the initial fragments. However, current literature is
insufficient to assign the special cleavage sites within semenogelin
to distinct exopeptidases [25].
Our study faces several limitations. Donation of seminal plasma
for diagnostic purposes is related to several practical issues. From
the present study we learned that between 30–50% of the patients
are willing and able to donate ejaculate before radical prostatic
surgery. However, we believe that acceptance will improve by
communicating the promising results of our preliminary study.
We could partially compensate missing compliance by the
inclusion of healthy volunteers and patients with chronic
prostatitis. Although these cohorts enabled us to confirm our
initial hypotheses that seminal plasma offers a robust source of
biomarkers, they might also have introduced some degree of bias
related to their age discrepancy compared to PCa and BPH
groups. In addition, our cross-sectional test cohorts are relatively
small and skewed. Therefore, future confirmatory studies should
mind well powered, balanced, and age-matched control cohorts
with clinical outcome data on PCa subtypes in follow-up. Based on
the small-scale test data presented here, sample size calculations
for such kind of study estimate a total sample size of 200 patients
with advanced or aggressive PCa and 302 patients with localized
indolent disease to demonstrate a minimal sensitivity and
specificity of 70% and 80% for advanced PCa, respectively.
Although using state-of-the-art tandem mass spectrometry, we
were unable to sequence all biomarker candidates. In contrast to
identification of parent proteins by tryptic peptide mass finger-
printing, native peptide sequencing is limited by post-translational
modifications, complicating not only peptide fragmentation, but
also subsequent database searches.
Conclusions
We were able to confirm our initial hypothesis that seminal fluid
is a robust source for the identification of PCa protein maker
profiles for primary diagnosis of prostate cancer. Our study
involves a two-step experimental approach with independent
discovery and test sets of samples in relation to post-surgery clinical
reference standard. This design is in line with current guidelines
for clinical proteome analysis [26]. Although our cohorts are
relatively small and selected, they were appropriate to assess the
feasibility of seminal profiling and to estimate the potential of
seminal peptides as diagnostic biomarkers. Therefore, the present
study should be understood as a very first step into the field of
seminal biomarkers. Our findings warrant further confirmatory
studies with enlarged unselected prospective validation cohorts to
confirm and to precise the diagnostic potential of the seminal
biomarker candidates and their (patho)physiological relevance.
Figure 3. Biomarker signatures. Normalized molecular weight (700–25.000 Da) in logarithmic scale is plotted against normalized migration time
(15–45 min). The mean signal intensity of the polypeptide peak is given in 3D-depiction. Averaged data sets of the training set are shown.
doi:10.1371/journal.pone.0067514.g003
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Materials, Patients and Methods
Ethics Statement
The study was approved by the Ethics Committee of the
University of Leipzig (Reg.No. 084-2009-20042009) and was
conducted according to the principles expressed in the Declaration
of Helsinki. Written informed consent was obtained from all
patients.
Study design and seminal plasma sampling
Exploitable seminal plasma samples were obtained from 70
patients with PCa, 21 patients with benign prostate hyperplasia
(BPH), 25 patients with chronic prostatitis (CP) and 9 healthy
controls (HC). As clinical reference standard we used a combina-
tion of histological workup of radical prostatectomy specimens for
post-surgery tumour grading and staging in PCa patients and
negative 10–12 needle prostate biopsy cores and/or negative
prostate resection specimens in BPH patients. All patients were
asked to donate seminal fluid prior to radical surgical resection of
the prostate, during infertility or urological diagnostics. For
biomarker discovery the available 125 samples were separated
into three study arms, one for diagnostic biomarkers (study A), a
second for advanced disease biomarkers with different training and
test sets (study B), and biomarker stability and reproducibility
(study C, Figure 1). In studies A and B, samples were either used
for discovery or for performance tests, but not both. Fifty samples
(22 PCa, 9 BPH, 14 CP, 5 HC) were used as training set for
diagnostic biomarker discovery (Table 1A), 75 samples were
included into the test set for testing diagnostic performance (48
PCa, 12 BPH, 11 CP, 4 HC, Table 1B). For advanced disease
biomarker discovery we divided the available 70 PCa samples into
a training set with 37 PCa samples (21 GS,7, 16 GS.7). The
remaining 33 samples with GS= 7 were used as a test set (28
,pT3a ‘‘indolent’’, 5 $pT3a ‘‘advanced’’).
We compared five different approaches for assessment of risk for
clinical PCa progression: based on the guidelines of the AUA [27]
who adopted the D’Amico criteria [28], the National Compre-
hensive Cancer Network (NCCN) criteria [29], the Radiation
Therapy Oncology Group (RTOG) criteria [30], the European
Association of Urology (EAU) guidelines [31], and the Cancer of
the Prostate Risk Assessment Score (CAPRA) score [32] (Table
S4). Seminal plasma samples were internally coded and analysed
in a blinded fashion (test set) after establishing biomarker profile
(training set).
In order to analyze pre-analytical stability of seminal plasma
obtained by this sampling protocol, a single sample of a patient
Figure 4. Biomarker performance validation. (A).Box and whisker plots of obtained 11PP results in the test cohort of PCa patients with GS 7
stratified according to TNM, (B) EAU, and (C) NCCN classification systems. Black squares indicate medians and whiskers 1.5-times the interquartile
ranges. Rank correlation coefficients rho, the respective 95% CI and P-values are given above. (D) ROC curve (black lines) for 11PP classification of the
independent validation cohort of PCa patients with GS 7 with either indolent (N = 28) or advanced (N= 5) disease according to EAU classification as
reference standard. 95% confidence intervals are plotted as dashed lines. Diagonal line represents guessing probability with an area under the curve
of 0.5. 95% confidence intervals (CI) are displayed as dashed lines.
doi:10.1371/journal.pone.0067514.g004
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harbouring PCa was thawed and prepared in two independent
replicates (study C). The rest of the sample was incubated at room
temperature. For six hours, every hour two replicates were
prepared. All 14 prepared replicates were lyophilized shortly after
preparation and re-suspended immediately before CE-MS anal-
ysis.
Analytical precision of the established SVM classifiers was
assessed by applying it to 15 CE-MS data sets obtained from
independent replicates of a sample of a 57 years old patient with
significant BPH. Prostate volume was 120 cc and total serum PSA
4.3 ng/mL. Results were expressed as mean and standard
deviation. Coefficients of variations were calculated by dividing
standard deviations by the observed overall range of SVM scores
[21PP from –1.50 to +1.50 (3.0 a.u.), 5PP from –4.50 to +3.0 (7.5
a.u.), and 11PP from –1.50 to +1.50 (3.0 a.u.)].
Sample procurement and proteomic analysis
Ejaculate was collected and allowed natural liquefaction to
occur by proteolysis at room temperature for 15 to 30 min.
Subsequently specimens were centrifuged at 4000 rpm for 10 min
to separate spermatozoa from seminal plasma. The supernatant
was then aliquoted into 50 ml aliquots and deep frozen at –80uC
until further processing.
Sample preparation
Immediately before preparation, seminal plasma samples were
thawed and protein concentration was adjusted to 2 mg/ml.
10 ml-replicates were lyophilized, stored at 4uC. Shortly before
CE-MS analysis the lyophilized replicates were suspended in 9 ml
high-performance liquid chromatography grade H2O and 1 ml
synthetic isotope-labelled peptide stock solution (Table S5) was
added [11] Isotope-labelled peptides were purchased from JPT
(Berlin, Germany). One 15N- and five 13C-isotopes were incorpo-
rated into a single proline residue (DM= +6). The C-termini of the
Figure 5. Assessment of biomarker stability and reproducibility. (A) An average of 18876202 polypeptides was detected in each of the 14
measurements stored for different times at RT. The mean is marked with a bold line; standard deviation is highlighted in grey. (B) Beyond this
qualitative assessment biomarker signatures were applied to the 14 stability replicates to obtain quantitative data of time-dependent stability of
seminal plasma. For 21PP ranked correlation analysis revealed a significant decrease of SVM scores over time with Spearman’s rho of –0.576 (95% CI –
0.854 to –0.07, P = 0.0379). Regression analysis unveiled a decrease rate of –0.05 a.u. (,2%) per hour. 5PP and 11PP displayed no significant time
dependency. (C) Analytical precision of the established SVM classifiers was assessed by applying it to 15 CE-MS data sets obtained from independent
replicates of a sample of a 57 years old patient with significant BPH. Mean classification scores were 0.61960.07, 2.29060.81, and -1.23960.18 for
21PP, 5PP, and 11PP respectively. Coefficients of variations were calculated by dividing standard deviations by the observed overall range of SVM
scores [highlighted in grey, 21PP from –1.50 to +1.50 (3.0 a.u.), 5PP from 4.50 to +3.0 (7.5 a.u.), and 11PP from –1.50 to +1.50 (3.0 a.u.)]. Coefficients of
variations were 2.2%, 10.8%, and 6.1%, respectively. Classification cut offs are represented by horizontal lines. The boxes depict means and standard
deviation as whiskers.
doi:10.1371/journal.pone.0067514.g005
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isotope-labelled peptides were synthesized with an amide function
(DM=–1). Therefore, the synthetic peptides had a total mass
difference of 5 atomic mass units. The injected amounts of
synthetic peptides are given in (Table S5).
CE-MS analysis
CE-MS analysis was performed as described earlier [33,34]. By
this procedure the limit of detection was ,1 fmol. Mass resolution
was above 8,000 enabling resolution of monoisotopic mass signals
for z#6. After charge deconvolution, mass accuracy was,25 ppm
for monoisotopic resolution and ,100 ppm for unresolved peaks
(z.6).
Data sets were accepted only if the following quality control
criteria were met: A minimum of 1000 peptides/proteins must be
detected with a minimum MS resolution of 8,000 (required
resolution to resolve ion signals with z = 6) in a minimum
migration time interval (the time window, in which separated
peptides can be detected) of 10 minutes (mean number time
interval minus one standard deviation). After calibration, the mean
deviation of migration time (compared to reference standards)
must be below 0.30 minutes.
Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software (www.proteomiques.com) [35]. For noise
filtering, signals with z.1 observed in a minimum of 3 consecutive
spectra with a signal-to-noise ratio of at least 4 were considered.
MosaiquesVisu employs a probabilistic clustering algorithm and
uses both isotopic distribution (for z#6) as well as conjugated
masses for charge-state determination of peptides/proteins. The
resulting peak list characterizes each polypeptide by its mass and
its migration time. After charge deconvolution, mass accuracy was
,25 ppm for monoisotopic resolution and ,100 ppm for
unresolved peaks (z.6). First we used 14 synthetic isotope labeled
peptides for data normalization. These peptides were added to
samples immediately before CE-MS analysis (Table S5). Secondly,
we calibrated the CE-MS data utilizing 287 reference mass data
points and migration time data points by applying global and local
linear regression, respectively. Ion signal intensity (amplitude) was
normalized relative to 46 reference signals of highly abundant
peptides using local linear regression (Table S1). The obtained
peak list characterizes each polypeptide by its calibrated molecular
mass [Da], calibrated CE migration time [min] and normalized
signal intensity. All detected peptides were deposited, matched,
and annotated in a Microsoft SQL database allowing further
statistical analysis. For clustering, peptides in different samples
were considered identical, if mass deviation was ,50 ppm for
small (,4,000 Da) or 75 ppm for larger peptides. Due to analyte
diffusion effect, CE peak widths increase with CE migration time.
For data clustering this effect was considered by linearly increasing
cluster widths over the entire electropherogram (19 min to 45 min)
from 2-5%.
After data normalization, all detected peptides were deposited,
matched, and annotated in a Microsoft SQL database. As
previously described for urine [36,37], several annotated peptides
appear sporadically, being observed in only one or a few samples.
To eliminate such peptides of apparently low significance, only
those peptides detected in more than 6 of the seminal plasma
samples in at least one group (samples from patients with same
disease) were further investigated. Applying these limits, a total of
1,784 relevant native peptides were clustered with a mass range
from 802.4 Da to 15,701.8 Da.
Descriptive Statistical analysis
Estimates of sensitivity and specificity were calculated based on
tabulating the number of correctly classified samples. Confidence
intervals (95% CI) were based on binomial calculations performed
with MedCalc version 8.1.1.0 (MedCalc Software, Belgium, www.
medcalc.be). The ROC plot was evaluated, as it provides a single
measure of overall accuracy that is not dependent upon a
particular threshold [38].
Differential statistical analysis
For statistical differential analysis we set a frequency threshold
of 60% for markers to be deemed valid in one of the considered
groups in order to be included in downstream analysis. Adjust-
ments for multiple testing [39] were done using the base 10
logarithm transformed intensities and the Gaussian approximation
to the t-distribution. For multiple testing corrections, p-values were
corrected using the false discovery rate procedure introduced by
Benjamini and Hochberg, which conserves sufficient statistical
power of looking for biomarkers that are differentially expressed
between two samples when subjected to two different treatments,
such as disease/no disease [40]. Proteins that were detected in a
diagnostic group of patients in at least 60% of samples were
considered. The test was implemented as macros in SAS (www.sas.
com) and are part of the multitest R-package www.bioconductor.
org [41].
Classification
MosaCluster (version 1.7.0) was developed for the discrimina-
tion between different patient groups. This software tool allows the
classification of samples in the high-dimensional parameter space
by using support vector machine (SVM) learning. For this purpose,
MosaCluster generates polypeptide models, which rely on
polypeptides displaying statistically significant differences when
comparing data from patients with a specific disease to controls or
other diseases, respectively. Each of these polypeptides allegorizes
one dimension in the n-dimensional parameter space [36,42–44].
SVM view a data point (probands urine sample) as a p-
dimensional vector (p numbers of protein used), and they attempt
to separate them with a (p-1) dimensional hyperplane. There are
many hyperplanes that might classify the data. However,
maximum separation (margin) between the two classes is of
additional interest, and therefore, the hyperplane with the
maximal distance from the hyperplane to the nearest data point
is selected. Therefore, all marker proteins are used without any
weighting to build up the n-dimensional classification space and to
display the data set in the classification space. Classification itself is
performed by determining the Euclidian distance of the data set to
the n-1 dimensional maximal margin hyperplane (absolute value
of the normal vector) and the direction of the vector (class 1 or
class 2).
Diagnostic cut-offs
For all biomarker patterns the threshold (cut-off) indicating the
transition from ‘‘negative’’ to ‘‘positive’’ was established based on
the classification results of the training set, considering analytical
variation of the system: This ensures a less than 15% chance that a
measurement with a true classification result of the threshold value
would give a false result above the cut-off. For 21PP the analytical
precision revealed a standard deviation SD (precision) of
approximately 0.30 a.u. The final cut-off was calculated as 0.30–
1SD=0.00 a.u. This cut-off was applied to the 75 samples of the
test set. Values below 0.00 were considered negative, values $0.00
positive. For 5PP the final cut-off was calculated as
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1.00+1SD=1.48 a.u. Values below 1.48 were considered negative
for BPH, values $1.48 positive. For 11PP the final cut-off was
calculated as 0.01+1SD=0.30 a.u. This cut-off was applied to the
33 samples of the test set. Values below 0.30 were considered as
indolent disease, values $0.30 as advanced disease.
Sequencing of peptides
Native peptides from seminal plasma were sequenced using LC-
MS/MS analysis. MS/MS experiments were performed using
higher energy collision dissociation (HCD) or electron transfer
dissociation (ETD) [12–14]. Peptides were separated on a Dionex
Ultimate 3000 RSLS nano flow system (Dionex, Camberly UK)
and introduced into an LTQ Orbitrap hybrid mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany) via nano-flow ESI,
as described in Metzger et al. [45]. Data files were searched
against the IPI human non-redundant database using the Open
Mass Spectrometry Search Algorithm (OMSSA, http://pubchem.
ncbi.nlm.nih.gov/omssa), with an e-value cut-off of 0.05 without
any enzyme specificity. No fixed modification was selected, and
oxidation of methionine were set as variable modifications.
Accepted parent ion mass deviation was 10 ppm; accepted
fragment ion mass deviation was 0.05 Da (for HCD) or 0.5 Da (for
ETD). For further validation of obtained peptide identifications,
the strict correlation between peptide charge at the working pH of
2 and CE-migration time was utilized to minimize false-positive
identification rates [46]: Calculated CE-migration time of the
sequence candidate based on its peptide sequence (number of basic
amino acids) was compared to the experimental migration time.
Peptides were accepted with a mass deviation below680 ppm and
a CE-migration time deviation below 62 min.
Supporting Information
Table S1 CE-MS data sets. For detected peptides identifica-
tion tag, calibrated mass in Da and migration time in min are
given. For all 125 patient data sets normalized signal amplitude
are listed, whereas ‘‘0’’ denotes undetected or missing values.
(XLS)
Table S2 Internal references. 46 seminal polypeptides were
used as internal references for signal amplitude normalization. ID:
polypeptide identifier annotated by the SQL database (ID), Amp:
Signal amplitude, CV: coefficient of variation of signal amplitudes.
(DOC)
Table S3 Seminal peptide sequence data. Tandem mass
spectrometry identified 141 native seminal peptides representing
47 different parental proteins. Fifthy-nine percent were fragments
of semenogelin-1 or -2, by far the most abundant peptides of the
low molecular weight seminal proteome. ID: polypeptide identifier
annotated by the SQL database (ID); Theo. Mass: theoretical mass
of the peptide sequence; delta CE/MS-M: Mass difference
between CE-MS experimental and theoretical mass normalized
to theoretical mass in parts per million [ppm]; delta MS/MS-M:
Mass difference between MS/MS experimental and theoretical
mass normalized to theoretical mass in parts per million [ppm]; m:
oxidized Methionine; CE/MS-Mass: CE-MS experimental mass
in Dalton [Da]; MS/MS-Mass [Da]: MS/MS experimental mass
in Dalton [Da]; E-value: Score used by OMSSA to rank hits for a
given MS/MS-spectrum.
(XLS)
Table S4 Risk assessment classification systems. In
clinical practice various classification systems are used to estimate
risk for prostate cancer progression. Therefore, we compared the
performance of our biomarkers to five commonly used systems,
namely AUA guidelines who adopted the D’Amico criteria, the
National Comprehensive Cancer Network (NCCN) criteria, the
Radiation Therapy Oncology Group (RTOG) criteria, the
European Association of Urology (EAU) guidelines, and the
Cancer of the Prostate Risk Assessment Score (CAPRA) score.
(DOC)
Table S5 Characteristics of synthetics peptide used for
pre-calibration of seminal plasma samples. Isotope
labelled proline residues are marked in bold italics. The amount
of each synthetic peptide added to the samples and averaged MS-
detected intensity are given.
(DOC)
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